すべての画像(1)
サイズを選択してください
表示を変更する
10 MG
￥20,900
50 MG
￥47,400
About This Item
実験式（ヒル表記法）:
C11H16FN3O3
CAS番号:
分子量:
257.26
MDL番号:
UNSPSCコード:
12352200
PubChem Substance ID:
NACRES:
NA.77
おすすめの製品
アッセイ
≥98% (HPLC)
フォーム
powder
色
white to off-white
溶解性
DMSO: >15 mg/mL
保管温度
2-8°C
SMILES記法
CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O
InChI
1S/C11H16FN3O3/c1-2-3-4-5-6-13-10(17)15-7-8(12)9(16)14-11(15)18/h7H,2-6H2,1H3,(H,13,17)(H,14,16,18)
InChI Key
AOCCBINRVIKJHY-UHFFFAOYSA-N
アプリケーション
Carmofur has been used as an inhibitor of acid ceramidase to study its effects on glucosylsphingosine (GlcSph) production in human embryonic kidney 293T (HEK293T) cells.[1] It has also been used as an inhibitor of acid ceramidase to study its effects on acid‐mediated hydrolysis of ceramide which kicks-in consumption and the generation of sphingosine [2].
生物化学的／生理学的作用
カルモフールは、フルオロウラシルの誘導体であり、抗悪性腫瘍薬として使用される代謝拮抗薬です。
カルモフールは、抗悪性腫瘍薬であり、フルオロウラシル類縁体です。
Carmofur acts as an inhibitor of fatty acid amide hydrolase (FAAH), N-acylethanolamine acid amidase (NAAA) and acid ceramidase (ASAH1).[3][4] Carmofur has a therapeutic activity against colorectal and cervical cancer.[5][4] It can inhibit the severe acute respiratory syndrome (SARS)-CoV-2 main protease (Mpro) in vitro.[5]
シグナルワード
Danger
危険有害性情報
危険有害性の分類
Acute Tox. 3 Oral - Repr. 2
保管分類コード
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
C1494-VAR:
C1494-10MG:
C1494-50MG:
C1494-BULK:
最新バージョンのいずれかを選択してください：
試験成績書（COA）
Lot/Batch Number
この製品を見ている人はこちらもチェック
Zhenming Jin et al.
Nature structural & molecular biology, 27(6), 529-532 (2020-05-10)
The antineoplastic drug carmofur is shown to inhibit the SARS-CoV-2 main protease (Mpro). Here, the X-ray crystal structure of Mpro in complex with carmofur reveals that the carbonyl reactive group of carmofur is covalently bound to catalytic Cys145, whereas its
Junichi Sakamoto et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22(3), 484-492 (2004-01-31)
Adjuvant therapy of colorectal cancer with oral fluorinated pyrimidines is attractive because of its ease of administration and good tolerability. The purpose of this meta-analysis is to assess the survival and disease-free survival benefits of treating patients after surgical resection
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
P Osterlund et al.
British journal of cancer, 87(6), 591-599 (2002-09-19)
We studied longitudinally inflammatory reactions and serum C-reactive protein (S-CRP) levels in 52 colorectal cancer patients treated with a median of six 3-weekly cycles of raltitrexed 1.5-3.0 mg m(-2) combined with oral carmofur (1-hexylcarbomoyl-5-fluorouracil) 300-400 mg m(-2) on cycle days
Nelson S Torres et al.
Antimicrobial agents and chemotherapy, 60(10), 5663-5672 (2016-07-13)
It is now well established that bacterial infections are often associated with biofilm phenotypes that demonstrate increased resistance to common antimicrobials. Further, due to the collective attrition of new antibiotic development programs by the pharmaceutical industries, drug repurposing is an
S Kuzuhara et al.
Journal of neurology, 234(6), 365-370 (1987-08-01)
Three cases of leucoencephalopathy induced by carmofur (1-hexylcarbamoyl-5-fluorouracil), an antineoplastic derivative of 5-fluorouracil are reported and the literature is reviewed. Initial symptoms were unsteady gait and dementia developing several weeks or months after carmofur had been started. Symptoms increased gradually
アクティブなフィルタ
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）
